BSLN Basilea Pharmaceutica AG

Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020

Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020
EN
12/10/2020

Underlying

BSLNBasilea Pharmaceutica AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Basilea Pharmaceutica AG

 PRESS RELEASE
Free
BSLN Basilea Pharmac...

Basilea erhält weitere USD 6 Mio. von BARDA zur Weiterentwicklung des ...

Basilea erhält weitere USD 6 Mio. von BARDA zur Weiterentwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 25. Februar 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die Biomedical Advanced Research and Development Authority (BARDA) der Administration for Strategic Preparedness and Response (ASPR) im U...

11h / 32m 1 EN
 PRESS RELEASE
Free
BSLN Basilea Pharmac...

Basilea receives further USD 6 million from BARDA to continue developm...

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Hea...

11h / 32m 1 EN
Free Trial
BSLN Basilea Pharmac...

Basilea Pharmaceutica AG: 1 director

A director at Basilea Pharmaceutica AG sold 600 shares at 54.678CHF and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

BSLN BASILEA PHARMACEUTICA AG
02/20/26 February 20, 2026 1 EN
 PRESS RELEASE
Free
BSLN Basilea Pharmac...

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft...

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance 15 % Anstieg der Lizenzeinnahmen 11 % Anstieg der GesamtumsätzeNettoliquidität verdreifacht Phase-3-Programm mit Fosmanogepix verläuft wie geplantGesamtumsatz und Betriebsgewinn 2026: zweistelliges Wachstum erwartetTelefonkonferenz und Webcast heute um 16 Uhr (MEZ) Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 17. Februar 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patien...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BSLN Basilea Pharmac...

Basilea reports strong 2025 full-year results, surpassing revenue and ...

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance 15% royalty income increase 11% total revenue increaseTripled net cash position Phase 3 program with fosmanogepix progressing as plannedFinancial guidance FY 2026: Double-digit increase in total revenue and operating profitConference call and webcast today at 4 p.m. (CET) Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 17, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharma company committed to meeting the needs of patients with sever...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch